28 assets in Aggressive B-Cell Non-Hodgkin Lymphoma

Therapeutic assets addressing Aggressive B-Cell Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rituximab Aggressive B-Cell Non-Hodgkin Lymphoma	Shanghai EpimAb Biotherapeutics Co., Ltd.	P3	BB (70)
Acalabrutinib Aggressive B-Cell Non-Hodgkin Lymphoma	Patrick C. Johnson, MD	P2	B (60)
Obinutuzumab Aggressive B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	B (60)
Zanubrutinib Aggressive B-Cell Non-Hodgkin Lymphoma	Prelude Therapeutics	P2	B (60)
Oxaliplatin Aggressive B-Cell Non-Hodgkin Lymphoma	Shanghai EpimAb Biotherapeutics Co., Ltd.	P2	B (59)
Venetoclax Aggressive B-Cell Non-Hodgkin Lymphoma	Prelude Therapeutics	P1/2	B (57)
Adriamycin Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Cyclophosphamide Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Etoposide Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Golcadomide Aggressive B-Cell Non-Hodgkin Lymphoma	Mayo Clinic	P2	CCC (53)
Jcar-017 Cd19-Specific Chimeric Antigen Receptor Aggressive B-Cell Non-Hodgkin Lymphoma	Patrick C. Johnson, MD	P2	CCC (53)
Nivolumab Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Prednisone Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Vincristine Sulfate Aggressive B-Cell Non-Hodgkin Lymphoma	David Bond, MD	P2	CCC (53)
Epcoritamab Aggressive B-Cell Non-Hodgkin Lymphoma	Genmab	P1/2	CCC (48)
Onct-808 Aggressive B-Cell Non-Hodgkin Lymphoma	Oncternal Therapeutics, Inc	P1/2	CCC (48)
CD47/SIRPA-BLOCKING AGENT ALX148 Aggressive B-Cell Non-Hodgkin Lymphoma	M.D. Anderson Cancer Center	P1/2	CC (47)
emb07 Aggressive B-Cell Non-Hodgkin Lymphoma	Shanghai EpimAb Biotherapeutics Co., Ltd.	P1/2	CC (47)
Lenalidomide Aggressive B-Cell Non-Hodgkin Lymphoma	M.D. Anderson Cancer Center	P1/2	CC (47)
prt2527 Aggressive B-Cell Non-Hodgkin Lymphoma	Prelude Therapeutics	P1	CC (47)
Mosunetuzumab Aggressive B-Cell Non-Hodgkin Lymphoma	Washington University School of Medicine	P1	CC (43)
nkx019 Aggressive B-Cell Non-Hodgkin Lymphoma	Nkarta, Inc.	P1	CC (43)
Synkir-310 Aggressive B-Cell Non-Hodgkin Lymphoma	Verismo Therapeutics	P1	CC (43)
68Ga-grazytracer Aggressive B-Cell Non-Hodgkin Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Al18F-NOTA-FAPI Aggressive B-Cell Non-Hodgkin Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Al18F-NOTA-grazytracer Aggressive B-Cell Non-Hodgkin Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Aggressive B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	NR ()
sys6055 Aggressive B-Cell Non-Hodgkin Lymphoma	Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd	P1/2	NR ()